target < targeted < targeting

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references

Number of relevant bibliographic references: 29.
[0-20] [0 - 20][0 - 29][20-28][20-40]

Ident.	Authors (with country if any)	Title
000003 (2020)	Charlotte Girard-Guyonvarc'H ; Michele Iudici	[Targeted therapies for connective tissue diseases and vasculitis].
000038 (2020)	Maria C. Cid [Espagne] ; Roberto Ríos-Garcés [Espagne] ; Nekane Terrades-García [Espagne] ; Georgina Espígol-Frigolé [Espagne]	Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies.
000061 (2020)	Ver Nica Cantarín-Extremera [Espagne] ; María Jiménez-Legido [Espagne] ; Anna Duat-Rodríguez [Espagne] ; Marta García-Fernández [Espagne] ; Nelmar Valentina Ortiz-Cabrera [Espagne] ; María Luz Ruiz-Falc Rojas [Espagne] ; Luis González-Gutiérrez-Solana [Espagne]	Tocilizumab in pediatric refractory status epilepticus and acute epilepsy: Experience in two patients.
000085 (2020)	Ran Li ; Kunchi Zhao ; Qing Ruan ; Chunyang Meng ; Fei Yin	The transcription factor Foxd3 induces spinal cord ischemia-reperfusion injury by potentiating microRNA-214-dependent inhibition of Kcnk2
000089 (2020)	Jacob J. Adashek [États-Unis] ; Shumei Kato [États-Unis] ; Scott M. Lippman [États-Unis] ; Razelle Kurzrock [États-Unis]	The paradox of cancer genes in non-malignant conditions: implications for precision medicine
000091 (2020)	Guillaume Decarriere [France] ; Thomas Barnetche [France] ; Bernard Combe [France] ; Cécile Gaujoux-Viala [France] ; Cédric Lukas [France] ; Jacques Morel [France] ; Claire Daien [France]	The most appropriate conventional DMARD to combine with different advanced therapies in rheumatoid arthritis: a systematic literature review with meta-analysis.
000109 (2020)	Eric Toussirot [France]	The Interrelations between Biological and Targeted Synthetic Agents Used in Inflammatory Joint Diseases, and Obesity or Body Composition
000113 (2020)	José M. Carballido [Suisse] ; Camille Regairaz [Suisse] ; Celine Rauld [Suisse] ; Layla Raad [Suisse] ; Damien Picard [Suisse] ; Michael Kammüller [Suisse]	The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases
000118 (2020)	Gregory S. Calip [États-Unis] ; Pritesh R. Patel [États-Unis] ; Karen Sweiss [États-Unis] ; Zhaoju Wu [États-Unis] ; Jifang Zhou [États-Unis] ; Alemseged A. Asfaw [États-Unis] ; Sruthi Adimadhyam [États-Unis] ; Todd A. Lee [États-Unis] ; Brian C-H Chiu [États-Unis]	Targets of biologic disease-modifying antirheumatic drugs and risk of multiple myeloma.
000123 (2020)	Huizhi Wang ; Zihang Chen ; Shaobo Wang ; Xiao Gao ; Mingyu Qian ; Wei Qiu ; Zongpu Zhang ; Shouji Zhang ; Yanhua Qi ; Xiaopeng Sun ; Hao Xue ; Xing Guo ; Rongrong Zhao ; Gang Li	TGFβ1‐induced beta‐site APP‐cleaving enzyme 2 upregulation promotes tumorigenesis through the NF‐κB signalling pathway in human gliomas
000141 (2020)	Adam Amlani [Canada] ; Claire Barber [Canada] ; Aurore Fifi-Mah [Canada] ; Jose Monzon [Canada]	Successful Treatment of Cytokine Release Syndrome with IL-6 Blockade in a Patient Transitioning from Immune-Checkpoint to MEK/BRAF Inhibition: A Case Report and Review of Literature.
000151 (2020)	Joanna Wai Yee Leong [Singapour] ; Peter P. Cheung [Singapour] ; Sajeewani Dissanayake [Singapour] ; Warren Weng Seng Fong [Singapour] ; Keng Hong Leong [Singapour] ; Ying Ying Leung [Singapour] ; Anita Yee Nah Lim [Singapour] ; Nai Lee Lui [Singapour] ; Mona Manghani [Singapour] ; Amelia Santosa [Singapour] ; Melonie Kannamma Sriranganathan [Singapour] ; Ernest Suresh [Singapour] ; Teck Choon Tan [Singapour] ; Gim Gee Teng [Singapour] ; Manjari Lahiri [Singapour]	Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
000195 (2020)	Linyu Geng [République populaire de Chine, États-Unis] ; Xiaojun Tang [République populaire de Chine] ; Shiying Wang [République populaire de Chine] ; Yue Sun [République populaire de Chine] ; Dandan Wang [République populaire de Chine] ; Betty P. Tsao [États-Unis] ; Xuebing Feng [République populaire de Chine] ; Lingyun Sun [République populaire de Chine]	Reduced Let-7f in Bone Marrow-Derived Mesenchymal Stem Cells Triggers Treg/Th17 Imbalance in Patients With Systemic Lupus Erythematosus
000197 (2020)	Angela Ceribelli [Italie] ; Francesca Motta [Italie] ; Maria De Santis [Italie] ; Aftab A. Ansari [États-Unis] ; William M. Ridgway [États-Unis] ; M. Eric Gershwin [États-Unis] ; Carlo Selmi [Italie]	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy
000202 (2020)	Giorgia Bucciol [Belgique] ; Isabelle Meyts [Belgique]	Recent advances in primary immunodeficiency: from molecular diagnosis to treatment
000208 (2020)	Natalia Maximova [Italie] ; Alessandra Maestro [Italie] ; Davide Zanon [Italie] ; Annalisa Marcuzzi [Italie]	Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration
000216 (2020)	Elaheh Kordzadeh-Kermani [Iran] ; Hossein Khalili [Iran] ; Iman Karimzadeh [Iran] ; Mohammadreza Salehi [Iran]	Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators
000258 (2020)	Peter N. Taylor [Royaume-Uni] ; Lei Zhang [Royaume-Uni] ; Richard W J. Lee [Royaume-Uni] ; Ilaria Muller [Royaume-Uni] ; Daniel G. Ezra [Royaume-Uni] ; Colin M. Dayan [Royaume-Uni] ; George J. Kahaly [Allemagne] ; Marian Ludgate [Royaume-Uni]	New insights into the pathogenesis and nonsurgical management of Graves orbitopathy.
000260 (2020)	Ruksana Huda	New Approaches to Targeting B Cells for Myasthenia Gravis Therapy
000312 (2020)	Clara Camaschella [Italie] ; Antonella Nai [Italie] ; Laura Silvestri [Italie]	Iron metabolism and iron disorders revisited in the hepcidin era
000320 (2020)	Rachel A. O Eefe ; Neil E. Bhola ; David S. Lee ; Daniel E. Johnson ; Jennifer R. Grandis	Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i -k "targeted" 

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i  \
                -Sk "targeted" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    targeted
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021